CorMedix (CRMD) | Stock Overview & Key Data
CorMedix Performance Comparison
Stock Range
Today's Range
Low: $12.79
High: $13.83
on September 9, 2025
52 Week Range
Low: $5.37
High: $17.43
on September 9, 2024
on June 23, 2025
All-Time High: $52.00 on March 30, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$989.6M
EPS
0.78
P/E Ratio (TTM)
15.90
Forward P/E
25.83
P/B Ratio
4.19
PEG Ratio
-0.07
Div. Yield
N/A
ROE
38.35%
Beta
1.766
Debt to Equity
0.20
Financial Highlights
Profitability
Gross Margin
95.31%
Operating Margin
49.18%
Profit Margin
42.11%
Returns and Earnings
Return on Assets (TTM)
19.87%
Return on Equity (TTM)
38.35%
EBITDA
$49.9M
Net Income (TTM)
$51.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$1.89
Quarterly Revenue Growth (YoY)
4,829.40%
Quarterly Earnings Growth (YoY)
4,829.40%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| CorMedix CRMD | 989.65M Small-cap | -12.91% | 23.43% | -11.15% | 18.83% | 55.11% | 83.45% | 277.22% | 176.57% |
| Vertex VRTX | 101.56B Large-cap | -1.43% | 7.83% | -11.41% | -20.95% | -2.59% | -18.57% | 36.43% | 48.93% |
| Regeneron REGN | 60.77B Large-cap | -3.37% | -0.81% | 7.89% | -25.02% | -21.92% | -51.58% | -21.38% | 0.58% |
| Adaptive ADPT | 1.98B Small-cap | -2.34% | 2.79% | 20.00% | 88.01% | 102.58% | 172.02% | 64.35% | -72.94% |
| Travere Therapeutics TVTX | 1.93B Small-cap | 16.80% | 25.15% | 42.19% | 18.63% | 11.76% | 57.27% | -20.21% | 4.69% |
| Immunocore Holdings IMCR | 1.87B Small-cap | 13.58% | 14.61% | 1.58% | 26.34% | 22.87% | 9.21% | -16.77% | -15.19% |
Ownership & Short Interest
Insider Ownership
7.49%
Institutional Ownership
46.79%
Shares Short
14M
Short Ratio
4.77
Short % of Shares Outstanding
19.19%
Average 10-Day Volume
6M
Average 90-Day Volume
4M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CRMD's 52-week high and low?
- In the last 52 weeks, CorMedix reached a high of $17.43 (on June 23, 2025) and a low of $5.37 (on September 9, 2024).
- What is the market cap and P/E ratio for CRMD?
- Curious about CorMedix's size and valuation? Its market capitalization stands at 989.65M. When it comes to valuation, the P/E ratio (trailing twelve months) is 15.90, and the forward P/E (looking ahead) is 25.83.
- Does CRMD pay dividends? If so, what's the yield?
- As for dividends, CorMedix isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are CorMedix's main competitors or similar companies to consider before investing?
When looking at CorMedix, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.56B Healthcare Biotechnology -18.57% 36.43% Regeneron
REGN60.77B Healthcare Biotechnology -51.58% -21.38% Adaptive
ADPT1.98B Healthcare Biotechnology 172.02% 64.35% Travere Therapeutics
TVTX1.93B Healthcare Biotechnology 57.27% -20.21% Immunocore Holdings
IMCR1.87B Healthcare Biotechnology 9.21% -16.77% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for CorMedix Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of CorMedix's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 38.35%, the Debt to Equity ratio from the most recent quarter is 0.20, and its Gross Profit Margin stands at 95.31%.
- What is the recent revenue and earnings growth for CRMD?
- Looking at CorMedix's growth, its revenue over the trailing twelve months (TTM) was $121M. Compared to the same quarter last year (YoY), quarterly revenue grew by 4,829.40%, and quarterly earnings saw a YoY growth of 4,829.40%.
- How much of CRMD stock is held by insiders and institutions?
- Wondering who owns CorMedix stock? Company insiders (like executives and directors) hold about 7.49% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 46.79%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.